Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

v3.21.2
Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Noncontrolling Interest [Line Items]          
NCI equity share $ 182,990   $ 182,990   $ 153,120
Net loss attributable to non-controlling interests (25,080) $ (14,417) (63,180) $ (41,264) (56,459)
Non-controlling interests in consolidated entities 119,810   119,810   96,661
FBIO Acquisition Corp VIII [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share (247)   (247)   (7)
Net loss attributable to non-controlling interests     (131)   (27)
Non-controlling interests in consolidated entities $ (378)   $ (378)   $ (34)
Non-controlling ownership 32.00%   32.00%   10.00%
Aevitas [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (4,049)   $ (4,049)   $ (2,370)
Net loss attributable to non-controlling interests     (751)   (823)
Non-controlling interests in consolidated entities $ (4,800)   $ (4,800)   $ (3,193)
Non-controlling ownership 45.90%   45.90%   39.00%
Avenue [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 2,058   $ 2,058   $ 5,800
Net loss attributable to non-controlling interests     (2,182)   (3,974)
Non-controlling interests in consolidated entities $ (124)   $ (124)   $ 1,826
Non-controlling ownership 77.50%   77.50%   77.40%
Baergic [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,995)   $ (1,995)   $ (1,662)
Net loss attributable to non-controlling interests     (29)   (97)
Non-controlling interests in consolidated entities $ (2,024)   $ (2,024)   $ (1,759)
Non-controlling ownership 39.50%   39.50%   39.50%
Cellvation [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,400)   $ (1,400)   $ (1,089)
Net loss attributable to non-controlling interests     (100)   (182)
Non-controlling interests in consolidated entities $ (1,500)   $ (1,500)   $ (1,271)
Non-controlling ownership 22.10%   22.10%   22.10%
Checkpoint [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 59,574   $ 59,574   $ 41,704
Net loss attributable to non-controlling interests     (20,618)   (13,265)
Non-controlling interests in consolidated entities $ 38,956   $ 38,956   $ 28,439
Non-controlling ownership 81.20%   81.20%   80.40%
Coronado SO [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (290)   $ (290)   $ (290)
Net loss attributable to non-controlling interests     0   0
Non-controlling interests in consolidated entities $ (290)   $ (290)   $ (290)
Non-controlling ownership 13.00%   13.00%   13.00%
Cyprium [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (1,276)   $ (1,276)   $ 567
Net loss attributable to non-controlling interests     (623)   (1,478)
Non-controlling interests in consolidated entities $ (1,899)   $ (1,899)   $ (911)
Non-controlling ownership 29.80%   29.80%   30.50%
Helocyte [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (5,401)   $ (5,401)   $ (4,986)
Net loss attributable to non-controlling interests     (65)   (259)
Non-controlling interests in consolidated entities $ (5,466)   $ (5,466)   $ (5,245)
Non-controlling ownership 18.30%   18.30%   18.80%
JMC [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 886   $ 886   $ 138
Net loss attributable to non-controlling interests     (2,339)   491
Non-controlling interests in consolidated entities $ (1,453)   $ (1,453)   $ 629
Non-controlling ownership 7.20%   7.20%   7.10%
Mustang [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ 136,441   $ 136,441   $ 116,060
Net loss attributable to non-controlling interests     (35,787)   (36,429)
Non-controlling interests in consolidated entities $ 100,654   $ 100,654   $ 79,631
Non-controlling ownership 82.40%   82.40%   80.90%
Oncogenuity [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (581)   $ (581)   $ (82)
Net loss attributable to non-controlling interests     (555)   (376)
Non-controlling interests in consolidated entities $ (1,136)   $ (1,136)   $ (458)
Non-controlling ownership 24.90%   24.90%   25.30%
Tamid [Member]          
Noncontrolling Interest [Line Items]          
NCI equity share $ (730)   $ (730)   $ (663)
Net loss attributable to non-controlling interests     0   (40)
Non-controlling interests in consolidated entities $ (730)   $ (730)   $ (703)
Non-controlling ownership 22.80%   22.80%   22.80%